Exact Mass: 1026.610181

Exact Mass Matches: 1026.610181

Found 68 metabolites which its exact mass value is equals to given mass value 1026.610181, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

PGP(a-25:0/PGF2alpha)

[(2S)-3-({[(2R)-2-{[(5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoyl]oxy}-3-[(22-methyltetracosanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C51H96O16P2 (1026.6173276)


PGP(a-25:0/PGF2alpha) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(a-25:0/PGF2alpha), in particular, consists of one chain of one 22-methyltetracosanoyl at the C-1 position and one chain of Prostaglandin F2alpha at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(PGF2alpha/a-25:0)

[(2S)-3-({[(2R)-3-{[(5E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]cyclopentyl]hept-5-enoyl]oxy}-2-[(22-methyltetracosanoyl)oxy]propoxy](hydroxy)phosphoryl}oxy)-2-hydroxypropoxy]phosphonic acid

C51H96O16P2 (1026.6173276)


PGP(PGF2alpha/a-25:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(PGF2alpha/a-25:0), in particular, consists of one chain of one Prostaglandin F2alpha at the C-1 position and one chain of 22-methyltetracosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(a-25:0/PGE1)

[(2S)-2-hydroxy-3-({hydroxy[(2R)-2-({7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoyl}oxy)-3-[(22-methyltetracosanoyl)oxy]propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C51H96O16P2 (1026.6173276)


PGP(a-25:0/PGE1) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(a-25:0/PGE1), in particular, consists of one chain of one 22-methyltetracosanoyl at the C-1 position and one chain of Prostaglandin E1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(PGE1/a-25:0)

[(2S)-2-hydroxy-3-({hydroxy[(2R)-3-({7-[(1R,2R,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl]heptanoyl}oxy)-2-[(22-methyltetracosanoyl)oxy]propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C51H96O16P2 (1026.6173276)


PGP(PGE1/a-25:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(PGE1/a-25:0), in particular, consists of one chain of one Prostaglandin E1 at the C-1 position and one chain of 22-methyltetracosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(a-25:0/PGD1)

[(2S)-2-hydroxy-3-({hydroxy[(2R)-2-({7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl}oxy)-3-[(22-methyltetracosanoyl)oxy]propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C51H96O16P2 (1026.6173276)


PGP(a-25:0/PGD1) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(a-25:0/PGD1), in particular, consists of one chain of one 22-methyltetracosanoyl at the C-1 position and one chain of Prostaglandin D1 at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   

PGP(PGD1/a-25:0)

[(2S)-2-hydroxy-3-({hydroxy[(2R)-3-({7-[(1R,2R,5S)-5-hydroxy-2-[(1E,3S)-3-hydroxyoct-1-en-1-yl]-3-oxocyclopentyl]heptanoyl}oxy)-2-[(22-methyltetracosanoyl)oxy]propoxy]phosphoryl}oxy)propoxy]phosphonic acid

C51H96O16P2 (1026.6173276)


PGP(PGD1/a-25:0) is an oxidized phosphoglycerophosphate (PGP). Oxidized phosphoglycerophosphates are glycerophospholipids in which a phosphoglycerol moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphoglycerophosphates belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphoglycerophosphates can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PGP(PGD1/a-25:0), in particular, consists of one chain of one Prostaglandin D1 at the C-1 position and one chain of 22-methyltetracosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PGPs can be synthesized via three different routes. In one route, the oxidized PGP is synthetized de novo following the same mechanisms as for PGPs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PGP backbone, mainely through the action of LOX (PMID: 33329396).

   
   
   
   

caminoside A

caminoside A

C49H86O22 (1026.5610456)


A glycolipid with an unusual non-glycerol aglycone, 10-hydroxynonadecan-2-one that is glycosylated at the C10 hydroxy group by a branched tetrasaccharide residue. It is isolated from the marine sponge Caminus sphaeroconia and exhibits potent activity as an inhibitor of a type III bacterial secretory system.

   

PIM1 36:1

2-O-(alpha-D-Manp)-(1-(9Z-octadecenoyl)-2-octadecanoyl-sn-glycero-3-phospho-1-myo-inositol)

C51H95O18P (1026.62557)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

[1-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

[1-[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C59H95O12P (1026.65608)


   

[1-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate

[1-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate

C59H95O12P (1026.65608)


   

[1-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate

[1-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoxy]-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate

C59H95O12P (1026.65608)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propan-2-yl] (11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propan-2-yl] (11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoate

C59H95O12P (1026.65608)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] (8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] (8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoate

C59H95O12P (1026.65608)


   

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propan-2-yl] (5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoate

[1-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propan-2-yl] (5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoate

C59H95O12P (1026.65608)


   

[1-[hydroxy-[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropoxy]phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] tetradecanoate

[1-[hydroxy-[2-hydroxy-3-[hydroxy-[2-hydroxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropoxy]phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] tetradecanoate

C51H96O16P2 (1026.6173276)


   
   
   
   
   
   

Ac2PIM1 17:1(methyl)_18:0(methyl)

Ac2PIM1 17:1(methyl)_18:0(methyl)

C51H95O18P (1026.62557)


   

[1-[hydroxy-[2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexyl]oxyphosphoryl]oxy-3-[(Z)-octadec-11-enoyl]oxypropan-2-yl] octadecanoate

[1-[hydroxy-[2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexyl]oxyphosphoryl]oxy-3-[(Z)-octadec-11-enoyl]oxypropan-2-yl] octadecanoate

C51H95O18P (1026.62557)


   

[1-[(Z)-heptadec-7-enoyl]oxy-3-[hydroxy-[2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] 10-methyloctadecanoate

[1-[(Z)-heptadec-7-enoyl]oxy-3-[hydroxy-[2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] 10-methyloctadecanoate

C51H95O18P (1026.62557)


   

DGDG(43:10)

DGDG(16:0_27:10)

C58H90O15 (1026.627939)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   
   
   
   
   
   

5,8,14,17,20-pentahydroxy-3-[hydroxy({1-[2-(oxiran-2-yl)propan-2-yl]indol-3-yl})methyl]-12-isopropyl-15-[methoxy(phenyl)methyl]-1,10,18-trimethyl-6-(4-methylpent-3-en-2-yl)-9,21-bis(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclohenicosa-4,7,13,16,19-pentaene-2,11-dione

5,8,14,17,20-pentahydroxy-3-[hydroxy({1-[2-(oxiran-2-yl)propan-2-yl]indol-3-yl})methyl]-12-isopropyl-15-[methoxy(phenyl)methyl]-1,10,18-trimethyl-6-(4-methylpent-3-en-2-yl)-9,21-bis(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclohenicosa-4,7,13,16,19-pentaene-2,11-dione

C56H82N8O10 (1026.6153592)


   

n-[38-(2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl)-2,4,6,8,10,12,14,16,18,20,22,24,26-tridecahydroxy-34,36-dimethyl-38-oxooctatriacont-36-en-1-yl]carboximidic acid

n-[38-(2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl)-2,4,6,8,10,12,14,16,18,20,22,24,26-tridecahydroxy-34,36-dimethyl-38-oxooctatriacont-36-en-1-yl]carboximidic acid

C53H90N2O17 (1026.6239170000001)


   

(3s,6s,9s,12s,15s,18s,21s)-5,8,14,17,20-pentahydroxy-3-[(r)-hydroxy(1-{2-[(2r)-oxiran-2-yl]propan-2-yl}indol-3-yl)methyl]-12-isopropyl-15-[(r)-methoxy(phenyl)methyl]-1,10,18-trimethyl-6-[(2r)-4-methylpent-3-en-2-yl]-9,21-bis(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclohenicosa-4,7,13,16,19-pentaene-2,11-dione

(3s,6s,9s,12s,15s,18s,21s)-5,8,14,17,20-pentahydroxy-3-[(r)-hydroxy(1-{2-[(2r)-oxiran-2-yl]propan-2-yl}indol-3-yl)methyl]-12-isopropyl-15-[(r)-methoxy(phenyl)methyl]-1,10,18-trimethyl-6-[(2r)-4-methylpent-3-en-2-yl]-9,21-bis(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclohenicosa-4,7,13,16,19-pentaene-2,11-dione

C56H82N8O10 (1026.6153592)


   

(2r,3r,4r,5r,6s)-6-{[(2r,3r,4s,6s)-6-{[(2r,3r,4s,6r)-6-{[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-1-[(1s)-1-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl]-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl (2e)-2-methylbut-2-enoate

(2r,3r,4r,5r,6s)-6-{[(2r,3r,4s,6s)-6-{[(2r,3r,4s,6r)-6-{[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-1-[(1s)-1-{[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl]-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl (2e)-2-methylbut-2-enoate

C53H86O19 (1026.5763006)


   

(2r,3r,4r,5r,6s)-6-{[(2r,3r,4s,6s)-6-{[(2r,3r,4s,6r)-6-{[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-1-[(1s)-1-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl]-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl (2e)-2-methylbut-2-enoate

(2r,3r,4r,5r,6s)-6-{[(2r,3r,4s,6s)-6-{[(2r,3r,4s,6r)-6-{[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-1-[(1s)-1-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl]-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-4-methoxy-2-methyloxan-3-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl (2e)-2-methylbut-2-enoate

C53H86O19 (1026.5763006)


   

(3s,6s,9s,12s,15s,18s,21s)-5,8,14,17,20-pentahydroxy-21-[(2r)-3-hydroxy-2-methylpropyl]-3-[(r)-hydroxy[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl]-12-isopropyl-15-[(r)-methoxy(phenyl)methyl]-1,10,18-trimethyl-6-[(2r)-4-methylpent-3-en-2-yl]-9-(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclohenicosa-4,7,13,16,19-pentaene-2,11-dione

(3s,6s,9s,12s,15s,18s,21s)-5,8,14,17,20-pentahydroxy-21-[(2r)-3-hydroxy-2-methylpropyl]-3-[(r)-hydroxy[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl]-12-isopropyl-15-[(r)-methoxy(phenyl)methyl]-1,10,18-trimethyl-6-[(2r)-4-methylpent-3-en-2-yl]-9-(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclohenicosa-4,7,13,16,19-pentaene-2,11-dione

C56H82N8O10 (1026.6153592)


   

6-({6-[(6-{[3a-hydroxy-9a,11a-dimethyl-1-(1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl)-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl)oxy]-4-methoxy-2-methyloxan-3-yl}oxy)-5-hydroxy-4-methoxy-2-methyloxan-3-yl 2-methylbut-2-enoate

6-({6-[(6-{[3a-hydroxy-9a,11a-dimethyl-1-(1-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}ethyl)-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl)oxy]-4-methoxy-2-methyloxan-3-yl}oxy)-5-hydroxy-4-methoxy-2-methyloxan-3-yl 2-methylbut-2-enoate

C53H86O19 (1026.5763006)


   

(2r)-2-{[(2s,3s,4e,6e,8s,9s)-3-{[(2s)-2-{[(2s,3r)-3-{[(2s,4s)-2-amino-1-hydroxy-4-methylhexylidene]amino}-3-carboxy-1-hydroxy-2-methylpropylidene]amino}-5-carbamimidamido-1-hydroxypentylidene]amino}-1-hydroxy-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dien-1-ylidene]amino}-4-[(1-{[(1r)-1-carboxyethyl]-c-hydroxycarbonimidoyl}eth-1-en-1-yl)(methyl)carbamoyl]butanoic acid

(2r)-2-{[(2s,3s,4e,6e,8s,9s)-3-{[(2s)-2-{[(2s,3r)-3-{[(2s,4s)-2-amino-1-hydroxy-4-methylhexylidene]amino}-3-carboxy-1-hydroxy-2-methylpropylidene]amino}-5-carbamimidamido-1-hydroxypentylidene]amino}-1-hydroxy-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dien-1-ylidene]amino}-4-[(1-{[(1r)-1-carboxyethyl]-c-hydroxycarbonimidoyl}eth-1-en-1-yl)(methyl)carbamoyl]butanoic acid

C50H78N10O13 (1026.5749538)


   

(3s,6s,9s,12s,15s,18s,21s)-5,8,14,17,20-pentahydroxy-21-[(2r)-3-hydroxy-2-methylpropyl]-3-{hydroxy[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-12-isopropyl-15-[(r)-methoxy(phenyl)methyl]-1,10,18-trimethyl-6-[(2r)-4-methylpent-3-en-2-yl]-9-(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclohenicosa-4,7,13,16,19-pentaene-2,11-dione

(3s,6s,9s,12s,15s,18s,21s)-5,8,14,17,20-pentahydroxy-21-[(2r)-3-hydroxy-2-methylpropyl]-3-{hydroxy[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-12-isopropyl-15-[(r)-methoxy(phenyl)methyl]-1,10,18-trimethyl-6-[(2r)-4-methylpent-3-en-2-yl]-9-(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclohenicosa-4,7,13,16,19-pentaene-2,11-dione

C56H82N8O10 (1026.6153592)


   

n-[(2s,4r,6r,8r,10r,12r,14r,16r,18r,20r,22r,24r,26s,34r,36z)-38-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-2,4,6,8,10,12,14,16,18,20,22,24,26-tridecahydroxy-34,36-dimethyl-38-oxooctatriacont-36-en-1-yl]carboximidic acid

n-[(2s,4r,6r,8r,10r,12r,14r,16r,18r,20r,22r,24r,26s,34r,36z)-38-[(2s)-2-benzyl-3-methoxy-5-oxo-2h-pyrrol-1-yl]-2,4,6,8,10,12,14,16,18,20,22,24,26-tridecahydroxy-34,36-dimethyl-38-oxooctatriacont-36-en-1-yl]carboximidic acid

C53H90N2O17 (1026.6239170000001)


   

8,10,16,20,23,24,26,28,30,32,34,36,38-tridecahydroxy-3,7,9,15,19,21,31,33-octamethyl-42-[1-(5-oxooxolan-2-yl)ethyl]-1-oxacyclodotetraconta-3,13,17,21,39-pentaen-2-one

8,10,16,20,23,24,26,28,30,32,34,36,38-tridecahydroxy-3,7,9,15,19,21,31,33-octamethyl-42-[1-(5-oxooxolan-2-yl)ethyl]-1-oxacyclodotetraconta-3,13,17,21,39-pentaen-2-one

C55H94O17 (1026.6490674)


   

(3e,5e,7s,8s,11e,13e,15s,16s)-8-[(2s,3r,4s)-4-[(2r,4r,5r,6r)-4-{[(2r,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-5-ethyl-2-hydroxy-6-methyloxan-2-yl]-3-hydroxypentan-2-yl]-16-[(2s,3r,4s)-4-[(2r,4r,5r,6r)-5-ethyl-2-hydroxy-6-methyl-4-{[(2r,4s,5s,6r)-4,5,6-trihydroxyoxan-2-yl]oxy}oxan-2-yl]-3-hydroxypentan-2-yl]-7,15-dimethyl-1,9-dioxacyclohexadeca-3,5,11,13-tetraene-2,10-dione

(3e,5e,7s,8s,11e,13e,15s,16s)-8-[(2s,3r,4s)-4-[(2r,4r,5r,6r)-4-{[(2r,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-5-ethyl-2-hydroxy-6-methyloxan-2-yl]-3-hydroxypentan-2-yl]-16-[(2s,3r,4s)-4-[(2r,4r,5r,6r)-5-ethyl-2-hydroxy-6-methyl-4-{[(2r,4s,5s,6r)-4,5,6-trihydroxyoxan-2-yl]oxy}oxan-2-yl]-3-hydroxypentan-2-yl]-7,15-dimethyl-1,9-dioxacyclohexadeca-3,5,11,13-tetraene-2,10-dione

C53H86O19 (1026.5763006)


   

5,8,14,17,20-pentahydroxy-21-(3-hydroxy-2-methylpropyl)-3-{hydroxy[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-12-isopropyl-15-[methoxy(phenyl)methyl]-1,10,18-trimethyl-6-(4-methylpent-3-en-2-yl)-9-(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclohenicosa-4,7,13,16,19-pentaene-2,11-dione

5,8,14,17,20-pentahydroxy-21-(3-hydroxy-2-methylpropyl)-3-{hydroxy[1-(2-methylbut-3-en-2-yl)indol-3-yl]methyl}-12-isopropyl-15-[methoxy(phenyl)methyl]-1,10,18-trimethyl-6-(4-methylpent-3-en-2-yl)-9-(2-methylpropyl)-1,4,7,10,13,16,19-heptaazacyclohenicosa-4,7,13,16,19-pentaene-2,11-dione

C56H82N8O10 (1026.6153592)


   

3-(acetyloxy)-6-{[4,5-dihydroxy-6-(hydroxymethyl)-2-[(2-oxononadecan-10-yl)oxy]oxan-3-yl]oxy}-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-2-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxan-4-yl butanoate

3-(acetyloxy)-6-{[4,5-dihydroxy-6-(hydroxymethyl)-2-[(2-oxononadecan-10-yl)oxy]oxan-3-yl]oxy}-5-[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]-2-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxan-4-yl butanoate

C49H86O22 (1026.5610456)